FDA launches safety review of Actos
September 20, 2010Sales and Marketing Actos, Takeda, diabetes
A new safety review of Takeda’s diabetes drug Actos has been launched by the FDA after a long-term study suggested …
Novartis hails longer-lasting COPD drug
September 20, 2010Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler
A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …
GSK workers in Ireland await review
September 20, 2010Manufacturing and Production, Research and Development GlaxoSmithKline, Ireland, job cuts
Workers at a GlaxoSmithKline facility in Ireland are anxiously awaiting the outcome of an official review of the operation amid …
Realising outsourcing’s potential
September 20, 2010Sales and Marketing Kinapse, White paper
IntroductionAs the budgets of pharma companies face continued downward pressure, the objective of outsourcing is not only to find effective …
Cellzome hires GSK’s Alan Watt
September 20, 2010Research and Development Cellzome, appointment, research and development
Cambridge, UK-based drug discovery and development company Cellzome has appointed Alan Watt to its senior management team as vice president …
Contract research news in brief
September 20, 2010Research and Development Covance, Galapagos, MediData Solutions, MediSync BioServices, PPD, Quotient Bioresearch, i3
A round-up of recent news from the CRO sector, featuring updates from Covance, Quotient Bioresearch, PPD, i3, Galapagos, MediSync BioServices …
Realising outsourcing’s potential
September 20, 2010IntroductionAs the budgets of pharma companies face continued downward pressure, the objective of outsourcing is not only to find effective …
Digital Pharma: Novo launches insulin dosing app
September 17, 2010Medical Communications, Sales and Marketing Digital Pharma blog, Novo Nordisk, app, diabetes, iphone
Novo Nordisk has launched an iPhone app for US healthcare professionals that enables to them look up dosing guidelines for …
J&J to acquire Crucell for $2.3 billion
September 17, 2010Sales and Marketing Crucell, Johnson & Johnson
Johnson & Johnson is set to buy out Crucell for around $2.3 billion (1.75 bn euros) expanding its presence in …
Triple account win for M:Communications
September 17, 2010Medical Communications Axis Shield, M:Communications, Medivir, Virgin Healthcare, medical communications
London-based communications consultancy M:Communications has won three new healthcare accounts. The new business comes from in vitro diagnostic company Axis-Shield, …
GSK switches to subcutaneous route for antibody
September 16, 2010Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab
GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
Norgine appoints global quality director
September 16, 2010Manufacturing and Production, Research and Development Norgine, appointment, manufacturing and production, research and development
Rosemarie Corrigan has joined European specialty pharmaceutical company Norgine as director of global quality, taking a leadership role across a …
MSD’s Dan Heapy joins MSI
September 16, 2010Sales and Marketing MSI, appointment, sales and marketing
The MSI Consultancy has appointed Dan Heapy as a consultant. He joins MSI from MSD, where over five years he …
Gene therapy advance hailed for thalassemia
September 16, 2010Research and Development Bluebird Bio, gene therapy, thalassemia
A new gene therapy for one of the most frequently inherited genetic disorders has produced promising results. The trial by …
Novo expands diabetes research in China
September 16, 2010Research and Development China, Novo Nordisk, diabetes
Diabetes is at the core of Novo Nordisk’s latest investment in China, where the company plans to more than double …
Digital Pharma: Lilly aims to be social on its Lillypad
September 16, 2010Medical Communications Digital Pharma blog, Twitter, blog, lilly
Lilly has jumped feet first into the social media scene this week, launching a corporate blog and a Twitter account. …
AstraZeneca’s Brilinta delayed
September 16, 2010Sales and Marketing Brillinta, Effient, Plavix, clopidogrel
AstraZeneca’s blood thinning drug Brilinta faces an extra three month delay to its review by the FDA. The US regulator …
Representing medium-sized pharma
September 16, 2010Sales and Marketing European Medicines Group, UCB
UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned pharma companies in the UK. …
GSK’s leukaemia drug rejected by NICE
September 16, 2010Sales and Marketing Arzerra, GSK, NHS, NICE
GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
